PharmaTimes | Industry News | World News | GSK signs OTC cold sore pact with Medivir, expands Prosensa deal
Xerclear (acyclovir/hydrocortisone) is the first and only topical herpes labialis treatment clinically proven to help prevent cold sore lesions appearing, the firms said. The combo was granted marketing approval in 14 European countries in October 2009 and based on strong clinical data, Xerclear was given “a unique label, which differentiates it from other topical cold sore products currently on the market,” GSK says.
The treatment, previously known as Lipsovir, will be distributed as part of GSK’s over-the-counter Zovirax (acyclovir) franchise in multiple markets, including Europe, Russia, Japan, India, Australia and New Zealand but not North and South America, China, South Korea and Israel. The drugs giant will pay up to 3 million euros in upfront and pre-launch milestones and up to double-digit royalties.
No comments:
Post a Comment